Antibody specifically binding to hemagglutinin of influenza a virus
By developing a bispecific antibody that specifically binds to the hemagglutinin of influenza A virus, and using a single-domain antibody fusion with human immunoglobulin Fc, the limitations of traditional antibody drugs have been overcome, achieving efficient, broad-spectrum neutralization and convenient administration.
Patent Information
- Application Number
- PCT/CN2026/080490
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-02-28
- Publication Date
- 2026-11-12
AI Technical Summary
Traditional monoclonal antibody drugs have limitations in treating influenza, such as insufficient broad spectrum, large molecular weight, and the need for intravenous injection. Furthermore, existing nebulized inhalation formulations have limited efficacy in treating influenza viruses, especially influenza A viruses.
A bispecific antibody that specifically binds to the hemagglutinin of influenza A virus was developed. The single-domain antibody was fused with human immunoglobulin Fc and administered via nebulized inhalation. It achieved a broad-spectrum neutralizing effect by binding to HA protein.
It achieves more precise targeted therapy, improves lung penetration and local drug concentration, enhances the broad-spectrum neutralizing ability against influenza A virus, and improves the convenience of medication.
Smart Images

Figure CN2026080490_12112026_PF_FP_ABST
Abstract
Description
An antibody that specifically binds to hemagglutinin of influenza A virus Technical Field
[0001] This invention relates to the field of biomedical technology, and in particular to an antibody that specifically binds to hemagglutinin of influenza A virus. Background Technology
[0002] Influenza viruses are one of the leading pathogens causing respiratory infections in humans. Based on their type, they can be classified into influenza A virus (IAV), influenza B virus (IBV), and influenza C virus (ICV), with most seasonal influenza infections caused by influenza A and B viruses. Influenza A virus, due to its high variability and ability to spread across species, is particularly prone to causing large-scale or even global epidemics. Influenza virus is a single-stranded, negative-sense, segmented RNA virus containing eight RNA segments that encode eight proteins. Among these, hemagglutinin (HA) and neuraminidase (NA), two membrane proteins, are the main targets of neutralizing antibodies. HA is responsible for the viral invasion process, while NA is involved in the release of the virus from host cells. In particular, the HA protein, as a key factor in viral invasion, has become an important target for developing influenza neutralizing antibodies.
[0003] Compared to small-molecule drugs, antibody drugs have demonstrated higher safety and stronger clearance effects in treating influenza. However, traditional monoclonal antibody drugs have limitations such as insufficient broad-spectrum activity, large molecular weight, and the need for intravenous administration. Given that influenza viruses primarily affect the respiratory tract and lungs, nebulized inhalation formulations offer a more effective treatment route, increasing local drug concentration and improving patient convenience and acceptance. Therefore, developing novel, highly effective, broad-spectrum neutralizing antibodies that can be administered via inhalation is particularly important for treating influenza viruses, especially influenza A viruses. Summary of the Invention
[0004] The purpose of this invention is to address the shortcomings of existing technologies by providing an antibody that specifically binds to hemagglutinin of influenza A virus.
[0005] To achieve the above objectives, the technical solution adopted by the present invention is as follows:
[0006] A first aspect of the present invention is to provide an antibody for specifically binding to influenza A virus hemagglutinin, comprising:
[0007] A single variable domain of the first immunoglobulin, or / and a single variable domain of the second immunoglobulin;
[0008] The first immunoglobulin single variable domain has a first variable domain with an amino acid sequence as shown in SEQ ID NO:1, a second variable domain with an amino acid sequence as shown in SEQ ID NO:2, and a third variable domain with an amino acid sequence as shown in SEQ ID NO:3.
[0009] The second immunoglobulin single variable domain has a fourth variable domain as shown in SEQ ID NO:4, a fifth variable domain as shown in SEQ ID NO:5, and a sixth variable domain as shown in SEQ ID NO:6.
[0010] SEQ ID NO:1: GFSFPFAA.
[0011] SEQ ID NO:2: ISATGDRI.
[0012] SEQ ID NO:3:NFPRGLEFLDDF.
[0013] SEQ ID NO:4: GSIFHING.
[0014] SEQ ID NO:5: IFSGGST.
[0015] SEQ ID NO:6: AARKWTGNVWAF.
[0016] Preferably, the amino acid sequence of the single variable domain of the first immunoglobulin is shown in SEQ ID NO:7-9.
[0017] SEQ ID NO:7: QVKLEESGGGLVQPGGSLRLSCVASGFSFPFAAMNWHRQVPGKERELVASISATGDRINYADSVKGRFTISRDNLKNTLYLQMSALKPEDSAVYYCNFPRGLEFLDDFWGQGTQVTVSS.
[0018] SEQ ID NO:8: EVQLVESGGGLVQPGGSLRLSCAASGFSFPFAAMSWVRQAPGKGLEWVSAISATGDRIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCNFPRGLEFLDDFWGQGTLVTVSS.
[0019] SEQ ID NO:9: EVQLVESGGGLVQPGGSLRLSCAASGFSFPFAAMNWVRQAPGKGLEWVSAISATGDRINYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCNFPRGLEFLDDFWGQGTLVTVSS.
[0020] Preferably, the amino acid sequence of the single variable domain of the second immunoglobulin is shown in SEQ ID NO:10.
[0021] SEQ ID NO:10: EVQLVESGGDSVQPGGSLRLSCVASGSIFHINGMGWYRQAPGRQRELVAAIFSGGSTNYADSVKGRFTISGDNAKNTAYLQMNSLKPEDTAVYYCAARKWTGNVWAFWGQGTQVTVSS.
[0022] Furthermore, the antibody is a bispecific antibody, which is composed of a first immunoglobulin single variable domain and a second immunoglobulin single variable domain connected by a linker. The C-terminus of the first immunoglobulin single variable domain is connected to the N-terminus of the second immunoglobulin single variable domain through a linker.
[0023] Furthermore, the amino acid sequence of the linker is shown in SEQ ID NO:11.
[0024] SEQ ID NO: 11: GGGGSGGGGSGGGGSGGGGS.
[0025] The amino acid sequence of the bispecific antibody is shown in SEQ ID NO:12.
[0026] SEQ ID NO:12:QVKLEESGGGLVQPGGSLRLSCVASGFSFPFAAMNWHRQVPGKERELVASISATGDRINYADSVKGRFTISRDNLKNTLYLQMSALKPEDSAVYYCNFPRGLEFLDDFWGQGTQVTVSSGGGGSGG GGSGGGGSGGGGSEVQLVESGGDSVQPGGSLRLSCVASGSIFHINGMGWYRQAPGRQRELVAAIFSGGSTNYADSVKGRFTISGDNAKNTAYLQMNSLKPEDTAVYYCAARKWTGNVWAFWGQGTQVTVSS.
[0027] A second aspect of the present invention is to provide a fusion protein, which is composed of the above-mentioned antibody fused with a heterologous protein.
[0028] Preferably, the heterologous protein is human immunoglobulin Fc, more preferably human IgG1 Fc.
[0029] A third aspect of the present invention is to provide a conjugate comprising the above-described antibody or the above-described fusion protein conjugated to an effector molecule.
[0030] Preferably, the effector molecule is a detectable label, more preferably a fluorescent label, a radioactive label, avidin, biotin, or an enzyme.
[0031] The present invention also provides a nucleotide molecule for encoding the aforementioned antibody. The present invention also provides a vector or recombinant vector comprising the nucleotide molecule, optionally and operably linked with a regulatory sequence. The present invention also provides a transformant comprising the vector or recombinant vector, and a method for producing and optionally recovering the antibody or antigen-binding fragment. The transformant described in the present invention can be any prokaryotic or eukaryotic cell, including but not limited to bacterial cells (e.g., *E. coli*), insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells (e.g., CHO or BHK cell lines). Other suitable transformants are known to those skilled in the art. *E. coli* cells are preferred as the transformant due to their short culture period and low production cost.
[0032] This invention also provides a pharmaceutical composition comprising: a preventive or therapeutically effective amount of the aforementioned antibody, or fusion protein, or conjugate, or nucleotide molecule, or carrier or recombinant carrier, or transformant, and a pharmaceutically or physiologically acceptable carrier, excipient, or stabilizer. The pharmaceutical composition includes, but is not limited to, lyophilized dosage forms, aqueous dosage forms, liposomes, or capsule dosage forms. The concentrations of the antibodies, bispecific antibodies, fusion proteins, conjugates, nucleotide molecules, carriers or recombinant carriers, and transformants described in this invention can vary from about 0.1 wt% to 100 wt%.
[0033] The present invention adopts the above technical solution and has the following technical effects compared with the prior art:
[0034] Compared with traditional IgG antibodies, this invention uses single-domain antibodies with relatively small molecular weight, which have better lung permeability and can recognize some hidden epitopes on antigens, thereby achieving more precise targeted therapy.
[0035] The bispecific antibody of this invention can broadly bind to influenza A virus HA and can broadly neutralize influenza A virus HA. Attached Figure Description
[0036] Figure 1 shows the results of ELISA detection of the binding of single-domain antibodies to the H1N1-HA protein of influenza A virus.
[0037] Figure 2 shows the results of ELISA detection of the binding of single-domain antibodies to the H3N2-HA protein of influenza A virus.
[0038] Figure 3 shows the neutralizing activity of the single-domain antibody against the live virus A / California / 07 / 2009(H1N1).
[0039] Figure 4 shows the neutralizing activity of the single-domain antibody against live A / Puerto Rico / 8 / 1934(H1N1) virus.
[0040] Figure 5 shows the neutralizing activity of the single-domain antibody against live A / WSN / 1933(H1N1) virus.
[0041] Figure 6 shows the neutralizing activity of the single-domain antibody against the live virus A / Guizhou / 54 / 1989(H3N2).
[0042] Figure 7 shows the detection of the neutralizing activity of single-domain antibodies against A / Qinghai / (H5N1) pseudovirus.
[0043] Figure 8 shows the detection of the neutralizing activity of single-domain antibodies against A / Thailand / (H5N1) pseudovirus.
[0044] Figure 9 shows the construction and validation of a broad-spectrum bispecific single-domain antibody.
[0045] Figure 10 shows the protective activity of the nebulized single-domain antibody against H1N1 influenza virus in mice.
[0046] Figure 11 shows the protective activity of the nebulized single-domain antibody against H3N2 influenza virus in mice.
[0047] Figure 12 shows the therapeutic protective activity of the nebulized single-domain antibody against H3N2 influenza virus in mice.
[0048] Figure 13 shows the SDS-PAGE images of the HA05 and HA06 sequences after humanization of 501.
[0049] Figure 14 shows the affinity of the humanized sequence HA06 to H1-HA as detected by BLI.
[0050] Figure 15 shows the neutralizing activity of the humanized sequence HA06 against the H1N1 strain as detected by microneutralization. Detailed Implementation
[0051] To gain a more thorough understanding of invention, some definitions are listed below. The definitions above are intended to include grammatically equivalent elements.
[0052] In this invention, "antibody" means a protein composed of one or more domains encoded by all or part of substantially well-known immunoglobulin genes. These well-known immunoglobulin genes, for example in humans, include kappa (κ), lambda (λ), and heavy chain loci containing numerous variable region genes and constant region genes mu (μ), delta (δ), gamma (γ), epsilon (ε), and alpha (α) respectively encoding IgM, IgD, IgG, IgE, and IgA isotypes. In this invention, "antibody" means a full-length antibody, its individual chains, and all parts, domains, or fragments thereof, as well as natural antibodies from any organism, engineered antibodies, or antibodies recombinantly produced for experimental, therapeutic, or other purposes further specified below. The term "antibody" includes antibody fragments known in the art, such as Fab, Fab', F(ab')2, Fv, scFv, or antigen-binding domains of antibodies (e.g., VHH or VH / VL domains), or antibody fragments generated by modifying intact antibodies or by resynthesizing antibodies using recombinant DNA technology. The term "antibody" includes both monoclonal and polyclonal antibodies. Antibodies can be antagonists, agonists, neutralizing antibodies, inhibitory antibodies, or stimulating antibodies. The antibodies of this invention can be nonhuman antibodies, chimeric antibodies, humanized antibodies, or fully human antibodies.
[0053] Specifically, non-glycosylated antibodies are included within the definition of "antibody." Preferably, the term "non-glycosylated antibody" used in this invention refers to an antibody lacking sugar attachment at position 297 of the Fc region, numbered according to Kabat's EU system. Non-glycosylated antibodies can be deglycosylated antibodies, which are antibodies with the Fc sugar removed, for example, by chemical or enzymatic methods. Optionally, the non-glycosylated antibody can be a non-glycosylated or unglycosylated antibody, which is an antibody without Fc sugar expression, for example, by mutating one or more residues encoding glycosylation or by expression in organisms that do not attach sugars to proteins, such as bacteria.
[0054] In this invention, "IgG" refers to a polypeptide belonging to the antibody class, which is essentially encoded by the well-known immunoglobulin γ gene. In humans, this class includes IgG1, IgG2, IgG3, and IgG4. In mice, this class includes IgG1, IgG2a, IgG2b, and IgG3. In this invention, "immunoglobulin (Ig)" refers to a protein composed of one or more polypeptides essentially encoded by the immunoglobulin gene. Immunoglobulins include, but are not limited to, antibodies. Immunoglobulins can have many structural forms, including, but not limited to, full-length antibodies, antibody fragments, and single immunoglobulin domains. Known Ig domains in the antibody IgG class include VH, Cγi, Cγ2, Cγ3, VL, and CL.
[0055] The term "antigen" as used in this invention refers to a compound, composition, or substance that can stimulate antibody production or T-cell response in an animal, including compositions injected or absorbed into the animal, and can be proteins, carbohydrates, lipids, or other pathogens.
[0056] In this invention, "single variable domain of immunoglobulin" refers to an immunoglobulin variable domain capable of specifically binding to an antigenic epitope without pairing with other immunoglobulin variable domains. An example of a single variable domain of immunoglobulin in this context is a "domain antibody," such as the VH domain antibody in this invention.
[0057] In this invention, the term "heavy chain variable region (VH)" refers to the region of the immunoglobulin heavy chain near the N-terminus where the amino acid sequence changes significantly; it is the heavy chain variable region structural domain in conventional four-chain antibodies. It is specifically used to distinguish VHH antibodies against camelids.
[0058] As used in this invention, "identity" refers to the similarity between nucleotide or amino acid sequences, also known as sequence identity. Sequence identity is typically measured as a percentage of identity (or similarity or homology); the higher the percentage, the more similar the two sequences. When aligned using standard methods, homologs or variants will have a relatively high degree of sequence identity. Sequence alignment methods used for comparison are well known in the art. Various procedures and alignment algorithms are described in: Smith and Waterman, Adv Appl. Math., 2:482, 1981; Needlema and Wunsch, J. Mol. Biol. 48:443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988; Higgins and Sharp, Gene 73:237-244, 1988; Higgins and Sharp, CABIOS 5:151-153, 1989; Corpet et al., Nucleic Acids Research 16:10881-10890, 1988; and Altschul et al., Nature Genet., 1994, 6:119-129.
[0059] The NCBI Basic Local Alignment Search Tool (BLAST™) is available from several sources (Altschul et al., J. Mol. Biol., 215: 403-410, 1990), including the National Center for Biotechnology Information (NCBI, Bethesda, Md.) and the Internet for the sequence analysis programs blastp, blastn, blastx, tblastn, and tblastx.
[0060] The term "bispecific antibody" used in this invention refers to an artificial antibody containing two specific antigen binding sites.
[0061] The term "fully human" as used in this invention means that the antibodies are entirely encoded by human antibody genes.
[0062] In this invention, "fusion protein" refers to the expression product of a fusion gene, or two or more proteins fused by biological or chemical methods.
[0063] In this invention, "conjugate" refers to an antibody or protein molecule that is linked to another small or large molecule by biological or chemical methods.
[0064] In this invention, "amino acid" refers to one of 20 naturally occurring amino acids or any non-natural analogue, which may be located at a specific position. In this invention, "protein" refers to at least two covalently linked amino acids, including proteins, polypeptides, oligopeptides, and peptides. Proteins may be composed of naturally occurring amino acids and peptide bonds, or of a synthetic peptide analogue structure, i.e., an "analyte." Therefore, in this invention, "amino acid" or "peptide residue" refers to naturally occurring and synthetic amino acids. For example, for the purposes of this invention, homophenylalanine, citrulline, and norleucine are considered amino acids for the purposes of this invention. "Amino acid" also includes imino acid residues such as proline and hydroxyproline. Side chains may be (R) or (S) configurations. In a preferred embodiment, amino acids are present in (S) or L-configurations. If non-naturally occurring side chains are used, non-amino acid substitutions may be used, for example, to prevent or delay in vivo degradation.
[0065] As used in this invention, "peptide" refers to a polymer in which monomers are amino acid residues linked together by amide bonds. When the amino acid is an α-amino acid, an L-optical isomer or a D-optical isomer may be used. The terms "peptide" or "protein" as used herein are intended to cover any amino acid sequence and include modified sequences, such as glycoproteins. The term "peptide" is particularly intended to cover naturally occurring proteins, as well as recombinant or synthetically produced proteins.
[0066] As used in this invention, "nucleotide" refers to a polymer composed of nucleotide units (ribonucleotides, deoxyribonucleotides, related naturally occurring structural variants and their synthetic non-natural analogs) linked by phosphodiester bonds. Therefore, the term includes nucleotide polymers, wherein the nucleotides and the bonds between them include non-natural synthetic analogs, such as, but not limited to, phosphate thioesters, aminophosphate esters, methylphosphate esters, chiral methylphosphate esters, 2'-O-methylribonucleotides, peptide nucleic acids (PNAs), etc. These polynucleotides can be synthesized, for example, using an automated DNA synthesizer. The term "oligonucleotide" generally refers to a short polynucleotide, typically no more than about 50 nucleotides. It should be understood that when the nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes RNA sequences in which "U" replaces "T" (i.e., A, U, G, C).
[0067] This invention uses conventional notation to describe nucleotide sequences: the left-hand 5' end of a single-stranded nucleotide sequence; the left-hand direction of a double-stranded nucleotide sequence is called the 5' direction. The direction in which 5' to 3' nucleotides are added to nascent RNA transcripts is called the transcription direction. The DNA strand with the same sequence as mRNA is called the coding strand.
[0068] In this invention, "plasmid" refers to a plasmid artificially constructed based on a natural plasmid to suit laboratory procedures. Nucleic acid molecules can be introduced into host cells to produce transformed host cells. The vector may include nucleic acid sequences that allow it to replicate in the host cell, such as an origin of replication, and may also include one or more selectable marker genes and other genetic elements known in the art.
[0069] The "host cell" used in this invention is also called the recipient cell, which refers to the host cell that receives foreign genes during transformation and transduction (infection).
[0070] As used in this invention, “pharmaceuticalally acceptable carrier” means a conventionally pharmaceutically acceptable carrier. Remington’s Pharmaceutical Sciences, EWMartin, Mack Publishing Co., Easton, Pa., 15th edition (1975) describes compositions and formulations suitable for drug delivery of one or more therapeutic compounds or molecules (e.g., one or more antibodies), as well as other pharmaceutical agents.
[0071] In this invention, "therapeutic effective amount" means a specific amount of a drug sufficient to achieve the desired effect in a subject treated with the drug. The precise dosage will depend on the purpose of treatment and can be determined by those skilled in the art using known techniques. Dosage ranges may be 0.01-100 mg / kg body weight or greater, for example 0.1, 1, 10, or 50 mg / kg body weight, preferably 1-10 mg / kg. As is known in the art, adjustments may be necessary for antibody or Fc fusion degradation, systemic or local drug delivery, and the rate of new protease synthesis, as well as age, weight, general health condition, sex, diet, timing of administration, drug interactions, and severity of illness, and can be determined by those skilled in the art using conventional experimental methods. Ideally, a therapeutically effective amount of antibody is an amount sufficient to prevent, treat, or improve an infection or disease. The therapeutically effective amount of a drug used for prevention, improvement, and / or treatment of a subject will depend on the subject being treated, the type and severity of the illness, and the manner of administration of the therapeutic composition.
[0072] As used in this invention, "encoding" refers to the inherent properties of a specific nucleotide sequence in a polynucleotide, such as a gene, cDNA, or mRNA, used as a template for the synthesis of other polymers and macromolecules in biological processes having a defined nucleotide sequence, or a defined amino acid sequence and the resulting biological properties. Thus, a gene encodes a protein if the transcription and translation of mRNA produced by that gene produces a protein in a cell or other biological system. The coding strand (whose nucleotide sequence is identical to the mRNA sequence and is generally provided in the sequence listing) and the non-coding strand (used as a transcription template, gene, or cDNA) can be referred to as encoding a protein, or other products of that gene or cDNA. Unless otherwise stated, "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate in form of each other and encode the same amino acid sequence. Nucleotide sequences encoding proteins and RNA may include introns.
[0073] Unless otherwise stated, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Unless the context clearly indicates otherwise, the singular terms “a,” “an,” and “the” include plural indicators. It should also be understood that all base sizes or amino acid sizes given for nucleic acids or polypeptides, and all molecular weights or molecular weight values, are approximate and provided for descriptive purposes. Although similar or equivalent methods and materials described in this invention may be used in the practice or testing of this disclosure, suitable methods and materials are described below. The term “comprising” means “including.” All publications, patent applications, patents, and other references mentioned in this invention are incorporated herein by reference in their entirety. In the event of any conflict, this specification (including the explanations of terms) shall prevail. Furthermore, materials, methods, and examples are illustrative only and not restrictive.
[0074] The standard recombinant DNA and molecular cloning techniques used in the examples are well-known in the art (Ausubel, FM et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley-Interscience), and the materials and methods suitable for microbial growth are also well-known in the art. Major chemical and biological reagents were purchased from KAPABiosystems, New England Biolabs, TransGen Biotech, Thermo Fisher Scientific, OMEGA bio-tek, etc.
[0075] The present invention will now be described in detail with reference to specific embodiments.
[0076] Example 1: Production of Influenza Virus Hemagglutinin (HA) Antigen Protein
[0077] HA base sequences from H1N1 (A / California / 07 / 2009) and H3N2 (A / New York / 55 / 2004) were fused with AVI-Tag, Folden, and 6×His sequences, respectively, to construct pTT expression vectors, which were then expressed in 293F cells (proteins were harvested 96 hours post-transfection). The cell supernatant was used to obtain the target proteins via Ni affinity chromatography, and the binding activity of the obtained proteins to known antibodies was verified by ELISA. Results showed that the purified H1N1-HA and H3N2-HA proteins achieved a purity of over 95% and possessed biological activity, ensuring the suitability for subsequent experiments.
[0078] Example 2: Screening for high-affinity single-domain antibodies against influenza A virus hemagglutinin HA antigen.
[0079] Alpacas were immunized five times at two-week intervals, immunized with H1N1-HA and H3N2-HA antigens respectively. After immunization, peripheral blood mononuclear cells (PBMCs) were isolated and their binding activity to different antigens was measured. With increasing immunization frequency, antibodies against H1N1-HA and H3N2-HA gradually accumulated in the alpacas. After immunization, blood was collected from the jugular vein and PBMCs were separated from the peripheral blood using density gradient centrifugation and Ficoll (a lymphocyte separation medium). Subsequently, magnetic bead sorting was used, employing anti-CD19+ antibody-conjugated magnetic beads to target CD19+ on the surface of B cells. + The specific affinity of the molecule was used to isolate B cells from the PBMC sample. The isolated B cells were first subjected to Trizol extraction for total RNA, followed by reverse transcription to synthesize the first strand of cDNA. Subsequently, a series of degenerate primers targeting single-stranded antibody amplification were designed, using the cDNA as a template to obtain the VH+CH2 fragment. Using this fragment as a template, further primers were designed to amplify the nanobody (VHH) fragment.
[0080] The VHH nucleic acid fragment was then cloned into the phage display vector pComb3x (Addgene, product number: 63891), and the ligation product was electroporated into E. coli electroporated competent cells TG1. The library size was approximately 10. 9 A single-domain antibody phage display library was created. Antibodies were then screened against biotin-labeled H1N1-HA and H3N2-HA proteins. The specific steps were as follows: Biotin-labeled HA proteins were immobilized on streptavidin-coated magnetic beads, and... 12 The antibody-displaying phages were incubated with 4 μg H1-HA, 2 μg H3-HA, and 1 μg H1-HA antigen for two hours in rounds 1, 2, and 3 at room temperature, respectively. Ten phages were used in each round of screening.12 Phages obtained in the third round of screening were used to infect TG1 cells, and clones were randomly selected for monoclonal phage ELISA. Further sequencing was performed to identify single-domain antibodies that bind to the HA protein.
[0081] The specific steps for monoclonal ELISA are as follows: Select the monoclonal clones obtained in the third round of screening into a 96-well shake plate, shake at 37℃ and 220rpm for 2-3 hours, then add 1:1000 IPTG and incubate overnight at 30℃ to induce expression. H1N1-HA and H3N2-HA proteins were coated at 100 μg per well in 96-well half-well plates (Corning), incubated overnight at 4°C, washed three times with 0.1% PBST, blocked with 3% milk for 1 hour, washed three times with 0.1% PBST, and then the bacterial culture prepared in the previous step was added as primary antibody. The mixture was incubated at 37°C for 1.5 hours, washed three times with 0.1% PBST, and then the anti-Flag-HRP (Sigma-Aldrich) secondary antibody diluted 1:5000 was added. The mixture was incubated at 37°C for 45 minutes, washed five times with 0.1% PBST, and then ABTS (Invitrogen) was added for color development. The OD405 value was read on a microplate reader. A positive single clone was defined as one with an OD value greater than 5 times that of the negative control. The bacterial culture of the positive single clone was sent to a sequencing company for sequencing.
[0082] Example 3: Detection of the binding ability of single-domain antibodies to H1N1-HA and H3N2-HA proteins
[0083] Positive single-domain antibody expression and purification: Based on sequencing results, sequence-enriched monoclonal antibodies were selected, and the preparation of their soluble expression products was basically carried out according to the literature (Cell Host Microbe. 2017. 22(4): 471-483.e5.). Specifically, the plasmid was transformed into HB2151 competent cells, a single colony was picked from an overnight ampicillin plate, inoculated into SB bacterial culture medium, and expressed for 12-14 hours under IPTG induction at 30℃. After bacterial lysis, the single-domain antibody was purified from the harvested bacteria using Ni-TNA (Yeasen Biotech).
[0084] Activity assay: 100 ng of HA protein was coated in a 96-well half-well plate (Corning) and incubated overnight at 4°C. After washing three times with 0.1% PBST, the plate was blocked with 3% milk for 1 hour, followed by three washes with 0.1% PBST. The plate was then incubated with single-domain antibodies starting at 2 μmol and serially diluted 3-fold for 1.5 hours, followed by three washes with 0.1% PBST. The plate was then incubated with anti-FLAG-HRP antibody (Sigma-Aldrich) for 45 minutes, followed by five washes with 0.1% PBST, and finally ABTS (Invitrogen) for color development. The results showed that single-domain antibody 501 (SEQ ID NO:7, the same below) had a strong binding ability to H1N1-HA protein (Figure 1), and single-domain antibody 602 (SEQ ID NO:10, the same below) had a strong binding ability to H3N2-HA protein (Figure 2).
[0085] Example 4: Detection of neutralizing activity of single-domain antibodies against different influenza A virus strains
[0086] First, live viruses A / California / 07 / 2009 (H1N1), A / Puerto Rico / 8 / 1934 (H1N1), A / WSN / 1933 (H1N1), and A / Guizhou / 54 / 1989 (H3N2) were amplified using MDCK cells. The amplification method was as follows: 2 mL of virus solution was added to adherent MDCK cells, and adsorption occurred for 1 hour. Then, 13 mL of virus amplification solution was added, and the cells were cultured at 37°C and 5% CO2 for 48 hours. The cell supernatant was collected as the amplified influenza virus. MDCK cells were seeded into 96-well cell culture plates. After adhesion, serially diluted virus stock solution was added to the MDCK cells, and the cells were cultured at 37°C and 5% CO2 for 18 hours. After culture, the viral load was quantified by detecting the viral NP protein level using ELISA. Finally, the viral titer was calculated using the Reed and Muench methods, yielding the TCID50 / 100 μL (refer to the WHO Influenza Manual for specific methods). The H5N1 pseudovirus amplification method was as follows: 293T cells were co-transfected with an HIV-1 backbone plasmid carrying the luciferase reporter gene deletion, along with HA and NA plasmids. The supernatant was harvested after 48 hours. The harvested pseudovirus was serially diluted and added to MDCK cells. After culturing for 12 hours, the medium was replaced with fresh medium, and the cells were cultured for another 48 hours. The relative fluorescence value in the cell lysate was then detected using the Promega Luciferase Assay Kit.
[0087] 1) The neutralization experiment of live toxin is as follows:
[0088] 50 μL of antibody, serially diluted 3-fold, was mixed with 50 μL of influenza virus diluted according to 100×TCID50 / 50 μL and incubated at 37°C for 1 hour. This mixture was then added to MDCK cells seeded in 96-well cell culture plates and incubated at 37°C with 5% CO2 for 18 hours. After incubation, the neutralizing activity of the antibody was assessed by detecting the amount of viral NP protein using an ELISA method.
[0089] 2) The pseudovirus neutralization experiment was as follows:
[0090] 50 μL of antibody, serially diluted 3-fold, was mixed with 50 μL of virus solution with a fluorescence value of approximately 200,000 and added to MDCK cells in a 96-well cell culture plate. The plate was incubated at 37°C and 5% CO2 for 12 hours, then replaced with fresh medium and incubated for another 48 hours. The relative fluorescence value in the cell lysate was detected using a Promega Luciferase Assay Kit.
[0091] The results showed (Figures 3-8) that single-domain antibody 501 could broadly neutralize live H1N1 virus and H5N1 pseudovirus, while single-domain antibody 602 (Figure 6), which can bind to H3N2-HA, could neutralize live A / Guizhou / 54 / 1989 (H3N2) virus.
[0092] Example 5: Construction and Validation of Bispecific Single-Domain Antibodies
[0093] The gene sequences of single-domain antibodies 501 and 602 were cloned into the prokaryotic expression vector pComb3x (Addgene, product number: 63891) via homologous recombination as shown in Figure 9A. The homologous recombination product was transformed into *E. coli* Top10 competent cells, and single colonies were picked and sequenced to obtain the correctly sequenced bispecific antibody expression vector. The constructed bispecific single-domain antibody plasmid was transformed into prokaryotic expression competent cells HB2151. Single colonies were picked from overnight-grown ampicillin plates, inoculated into SB bacterial culture, and expressed for 12-14 hours under IPTG induction at 30°C. The bacteria were harvested and the bispecific single-domain antibody was purified from them using Ni-NTA (purchased from GE Healthcare).
[0094] The binding activity of the bispecific single-domain antibody HA23 (SEQ ID NO: 12) to H1N1-HA and H3N2-HA proteins was determined using BLI technology (Emerg Microbes Infect. 2017. 6(10): e89.). The HA antigen obtained in Example 1 was specifically biotin-labeled (APExBIO, product number: K4402). The biotin-labeled HA antigen was immobilized on an SA sensor (Pall Fortebio), and serially diluted HA23 protein solutions were used as analytical samples. The steps were as follows: HA protein was diluted to 15 μg / ml and then immobilized on an SA biosensor. Binding was performed with 3-fold serially diluted HA23 protein solutions (concentration range 500-18.5 nM or 200-7.4 nM) in running buffer (PBST). No antibody was added to the blank control wells. The program settings were: Association, 300 s; Dissociation, 300 s, temperature set at 37 °C. The data were analyzed using ForteBio Data Analysis 10.1 software. The corresponding blank control wells were used as controls to subtract background. The curves for each concentration were fitted according to the Mass Transport binding mode to obtain the kinetic analysis results. The report displays the binding equilibrium constant (K0). D The value shows a K value similar to that of H1N1-HA. D The K0 is 0.46 nM, and it is similar to that of H3N2-HA. D It is 3.78 nM (Figure 9B).
[0095] The neutralizing activity of HA23 against different influenza A virus strains was detected using the above-mentioned virus neutralization experiment. The results showed that HA23 had neutralizing activity against live virus A / California / 07 / 2009(H1N1); live virus A / Puerto Rico / 8 / 1934(H1N1); live virus A / WSN / 1933(H1N1); live virus A / Guizhou / 54 / 1989(H3N2); pseudovirus A / Qinghai / (H5N1); and pseudovirus A / Thailand / (H5N1) (Figure 9C).
[0096] Example 6: Protective activity of nebulized inhaled single-domain antibody against influenza A virus
[0097] First, 6-8 week old female Babl / c mice were infected with different titers of A / Puerto Rico / 8 / 1934 (H1N1) and A / Guizhou / 54 / 1989 (H3N2) viruses to verify the median lethal dose (LD50) of the virus in mice.
[0098] The efficacy of single-domain antibodies in preventing and protecting against A / Puerto Rico / 8 / 1934 (H1N1) virus infection in mice was verified using nebulized inhalation. One day before nasal infection with 10 LD50 A / Puerto Rico / 8 / 1934 (H1N1) virus, mice were nebulized with 25 mg / kg of antibodies (501, 602, HA23, 501+602) and PBS (Figure 10A). Body weight and survival rate were continuously monitored for 14 days post-infection. Mice nebulized with PBS or the irrelevant antibody 602 (an antibody without neutralizing activity against H1N1) all died within 7-8 days post-infection (weight loss greater than 25%), while mice nebulized with the broad-spectrum single-domain antibody HA23 (targeting HA) survived completely without significant weight loss (Figures 10C-D). On day 5 post-infection, half of the mice were sacrificed, and lung tissue was collected for qPCR to detect the viral M2 gene copy number. The viral copy number in the lung tissue of mice in the nebulized drug administration group was significantly reduced by 10,000-fold compared with the nebulized PBS and unrelated antibody groups (Figure 10B).
[0099] Next, we verified the protective effect of nebulized broad-spectrum single-domain antibody against A / Guizhou / 54 / 1989(H3N2) virus infection in mice. Similar to previous animal experiments, mice were nebulized with 25 mg / kg of antibodies (501, 602, HA23, 501+602) and PBS one day before nasal infection (Figure 11A). On the fifth day after infection, half of the mice in each group were sacrificed, and lung tissue was collected. The copy number of the viral genome M2 gene in the lung tissue was detected by qPCR. The results showed that the copy number of the viral genome in the lungs of mice in the nebulized broad-spectrum anti-HA single-domain antibody group was significantly lower than that in the PBS group and the unrelated antibody group (Figure 11B). Monitoring of mouse body weight and survival rate showed that the body weight of mice in the nebulized broad-spectrum anti-HA single-domain antibody group did not decrease significantly, and all mice survived (Figures 11C-D).
[0100] Example 7: Therapeutic protective activity of nebulized inhaled single-domain antibody against influenza A virus
[0101] The therapeutic efficacy of the screened single-domain antibodies against influenza A / Guizhou / 54 / 1989(H3N2) virus infection was further validated by nebulized inhalation. The experimental design is shown in Figure 12A. Five hours after infecting mice with a lethal dose of virus, the mice were nebulized with the first antibody drug (25 mg / kg, 501, 602, HA23, 501+602). The antibody drug was then nebulized again on days 1 and 2. Mouse body weight and productivity were continuously monitored for 14 days. On day 5, half of the mice were sacrificed, and lung tissue was collected. The viral gene copy number in the mouse lung tissue was detected using qPCR. Body weight and survival rate monitoring data showed that the mice in the nebulized single-domain antibody group did not show a significant decrease in body weight, and all mice survived. In contrast, the mice in the nebulized PBS or control antibody groups all experienced a decrease in body weight to less than 25% on day 5, and all mice died (Figures 12C-D). Furthermore, qPCR results showed that the viral gene copy number in the PBS group and the control group was significantly higher than that in the antibody group with therapeutic effect (Figure 12B).
[0102] Example 8
[0103] Humanized HA05 (SEQ ID NO:8) and HA06 (SEQ ID NO:9) were constructed on the pComb3X vector and transfected into HB2151 competent cells. Single colonies were picked from overnight-grown ampicillin plates and inoculated into SB bacterial culture medium. Expression was performed at 30℃ under IPTG induction for 12-14 hours. After bacterial lysis, single-domain antibodies were purified using Ni-TNA (Yeasen Biotech). 6 μg of single-domain antibody protein was mixed with 5X SDS-PAGE loading buffer and loaded onto a 12-well protein precast gel (Smart-Lifesciences). Electrophoresis was performed at 160V for 30 minutes. Coomassie Brilliant Blue staining solution (Beyotime Biotech) was added to the gel, and staining was performed at room temperature for 10 minutes. The gel was then destained in double-distilled water until clear bands were visible. As shown in Figure 13, the molecular weight of the humanized single-domain antibody was approximately 15 kDa, with a single band and good purity. The binding activity of humanized antibody HA06 to H1N1-HA protein was determined using BLI technology (Cell Host Microbe. 2020; 27(6):891-898.e5). Biotin-labeled H1N1-HA antigen was immobilized on an SA sensor (Pall Fortebio), and serially diluted HA06 protein solutions were used as analytical samples. The procedure was as follows: HA protein was diluted to 15 μg / ml and then immobilized on the SA biosensor. Binding was performed with 3-fold serially diluted HA06 protein solutions (concentration range 1000 nM-37 nM) in running buffer (PBST). No antibody was added to the blank control wells. The program settings were: Association, 300 s; Dissociation, 300 s, temperature set to 37 °C. ForteBio Data Analysis 10.1 software was used for data analysis. Using the corresponding blank control wells as controls to subtract background, the curves for each concentration were fitted according to the Mass Transport binding mode to obtain the kinetic analysis results. The report shows the equilibrium constant (KD) value of the binding, and the results show that the KD for H1N1-HA is 0.87 nM (Figure 14). The neutralizing activity of HA06 against influenza A virus strains was detected by a microneutralization virus neutralization assay. The results showed that the neutralizing activity of the 501 humanized sequence HA06 against live A / California / 07 / 2009 (H1N1) virus was comparable to that of 501 (Figure 15).
[0104] The above description of the disclosed embodiments enables those skilled in the art to implement or use the present invention. The above description is merely a preferred embodiment of the present invention. It should be noted that those skilled in the art can make various improvements and additions without departing from the principles of the present invention, and these improvements and additions should also be considered within the scope of protection of the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined in the present invention can be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. An antibody for specifically binding to hemagglutinin of influenza A virus, characterized in that, include: A single variable domain of the first immunoglobulin, or / and a single variable domain of the second immunoglobulin; The first immunoglobulin single variable domain has a first variable domain with an amino acid sequence as shown in SEQ ID NO:1, a second variable domain with an amino acid sequence as shown in SEQ ID NO:2, and a third variable domain with an amino acid sequence as shown in SEQ ID NO:
3. The second immunoglobulin single variable domain has a fourth variable domain as shown in SEQ ID NO:4, a fifth variable domain as shown in SEQ ID NO:5, and a sixth variable domain as shown in SEQ ID NO:
6.
2. The antibody according to claim 1, characterized in that, The amino acid sequence of the single variable domain of the first immunoglobulin is shown in SEQ ID NO:7-9.
3. The antibody according to claim 1, characterized in that, The amino acid sequence of the single variable domain of the second immunoglobulin is shown in SEQ ID NO:
10.
4. The antibody according to claim 1, characterized in that, The C-terminus of the first immunoglobulin single variable domain is connected to the N-terminus of the second immunoglobulin single variable domain via a linker.
5. A fusion protein, characterized in that, The antibody according to any one of claims 1-4 is fused with a heterologous protein.
6. The fusion protein according to claim 5, characterized in that, The heterologous protein is human immunoglobulin Fc.
7. A coupling, characterized in that, The antibody according to any one of claims 1-4, or the fusion protein according to any one of claims 5-6, is coupled to an effector molecule.
8. The coupling according to claim 7, characterized in that, The effector molecule is a detectable label.
9. A nucleotide molecule, characterized in that, The antibody is encoded as described in any one of claims 1-4.
10. A vector or recombinant vector, characterized in that, include: The nucleotide molecule as described in claim 9.
11. A transformant, characterized in that, include: The vector or recombinant vector as described in claim 10, or the gene of the transformant having the nucleotide molecule as described in claim 9 integrated thereon.
12. A pharmaceutical composition comprising: The effective amount of the antibody according to any one of claims 1-4, or the fusion protein according to any one of claims 5-6, or the conjugate according to any one of claims 7-8, or the nucleotide molecule according to claim 9, or the vector or recombinant vector according to claim 10, or the transformant according to claim 10, and a pharmaceutically acceptable vector.
